BIQUIN DURULES 250 MG 250 MG
QUINIDINE ACID SULFATE : 250 MG · DIN 00249580 · ASTRAZENECA CANADA INC
Health Canada status: CANCELLED POST MARKET
What is BIQUIN DURULES 250 MG?
BIQUIN DURULES 250 MG 250 MG contains QUINIDINE ACID SULFATE : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 00249580, held by ASTRAZENECA CANADA INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 07-Aug-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00249580 |
|---|---|
| Brand name | BIQUIN DURULES 250 MG |
| Generic / active ingredient | QUINIDINE ACID SULFATE : 250 MG |
| Manufacturer | ASTRAZENECA CANADA INC |
| Strength | 250 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Ethical |
| ATC code | C01BA01 QUINIDINE |
| AHFS class | 24:04.04.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 07-Aug-2008 |
| Original market date | 1972-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C01BA01 QUINIDINE. 0 of 17 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO QUINIDINE TAB 200MG | 200 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00441740 |
| APO-QUIN-G TAB 325MG | 325 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00595934 |
| CARDIOQUIN TABLETS | 275 MG | TABLET | PURDUE PHARMA | CANCELLED POST MARKET | DIN 00026131 |
| NATISEDINE TAB 100MG | 100 MG | TABLET | SABEX INC | CANCELLED POST MARKET | DIN 00392901 |
| NOVO-QUINIDIN 200MG | 200 MG | TABLET | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00021733 |
| PROSEDYL TAB 100MG | 100 MG | TABLET | ROUGIER PHARMA DIVISION OF RATIOPHARM INC | CANCELLED POST MARKET | DIN 01928767 |
| QUINATE TAB 325MG | 325 MG | TABLET | ROUGIER PHARMA DIVISION OF RATIOPHARM INC | CANCELLED POST MARKET | DIN 00311731 |
| QUINIDEX EXTENTABS SRT 300MG | 300 MG | TABLET (EXTENDED-RELEASE) | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | DIN 02043505 |
| QUINIDEX EXTENTABS SRT 300MG | 300 MG | TABLET (EXTENDED-RELEASE) | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 01913883 |
| QUINIDINE 200 TAB | 200 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00563692 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.